(NASDAQ:BCDA), Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance Statistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with […]

(NASDAQ:INAB), NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR)

(NasdaqGM:BIOR), SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from

NASHVILLE, Tenn., March 31, 2025 (GLOBE NEWSWIRE) — 360 Privacy, provider of the leading digital executive protection platform, today announced the appointment of three key executives to strengthen its leadership team. These strategic appointments will support the company's ambitious growth plans following its recent funding round from FTV Capital and advance its mission to provide

(NASDAQ:AMRN), DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial

(NASDAQ:NDAQ), NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Nasdaq today released a comprehensive set of policy recommendations in a paper titled “Advancing the U.S. Public Markets: Unlocking Capital Formation for a Stronger American Economy.” The paper draws insights from a recent survey and ongoing engagement with thousands of Nasdaq-listed companies and advances critical policy

(TSX-V:CLIP),(OTC US:CLPMF),(Other OTC:CLPMF), TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP; OTCQB: CLPMF) (“Clip Money” or the “Company“), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the fiscal year ended December 31, 2024. The Company reported record revenue growth in

(NASDAQ:CGON), – Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology – – Additional updates from across CG Oncology's clinical trial program, including translational data, planned – IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage

(NYSE:EBS), GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our

(NASDAQ:PHAT), For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD1 A Media Snippet accompanying